Authors
Latest:
Is there a difference between MD and DO in urology?"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Latest:
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer“There are a lot of variables and factors in deciding what might be the entire first-line of therapy," says Adam B. Weiner, MD.
Latest:
Sarah Psutka, MD, on phase 3 trial of padeliporfin VTP therapy in UTUC“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practiceIn this video, part 5 in a 5-part series, panelists examine the economic and logistical realities of bringing mitomycin for intravesical solution (Zusduri; formerly UGN-102) into private practice.
Latest:
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testingAPPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.
Latest:
Experts discuss expanding use of vibegron for OABGrace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.
Latest:
What steps can physicians take to overcome barriers to health equity?“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.
Latest:
Expert shares anticipated research directions for PSMA-PET in prostate cancer"I would basically look at these 3 things as the major things to be coming up," says Jitesh Dhingra, MD, FRCEM.
Latest:
177Lu-PSMA-617 prolongs rPFS in taxane-naïve mCRPC, benefit greater with prior abiraterone vs enzalutamideLutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.
Latest:
Brendan Frainey, MD, on microbiome composition in patients with spina bifida"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says Brendan T. Frainey, MD.
Latest:
Kara Watts, MD, outlines SUO 2024 session on salvage focal ablation"I think the highlights are the functional outcomes after a salvage focal ablation are favorable, definitely, compared to salvage radical prostatectomy, but the studies are quite limited in terms of real salvage focal ablation," says Kara L. Watts, MD.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
Potential Impact of PET/CT Imaging on Improving Patient CareNeal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.
Latest:
Current Shortcomings in the Modern Urology Practice Management LandscapeA urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.
Latest:
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert PanelPanelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and optimized therapy sequencing to improve outcomes, as current approaches still leave many patients at risk of relapse despite expanding therapeutic options.
Latest:
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert PanelPanelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and optimized therapy sequencing to improve outcomes, as current approaches still leave many patients at risk of relapse despite expanding therapeutic options.
Latest:
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal TherapyPanelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings"We have communicated with Solventum, who makes this software, and they have made changes based on our feedback," says Timothy D. Lyon, MD.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Low-Grade, Intermediate-Risk NMIBC: The Hidden LesionPanelists discuss how UGN-102, a reverse thermal hydrogel formulation of mitomycin, offers an FDA-approved ablative treatment option for patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC), demonstrating 80% complete response rates in the ENVISION trial (NCT05243550) and allowing for the de-escalation of surveillance and reduced surgical burden.
Latest:
Balancing the benefits and risks of AI in health care“The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs,” writes cybersecurity expert Jon Moore.
Latest:
Expert shares tips for safeguarding your practice when using telehealthHealth care practitioners utilizing telemedicine, regardless of the modality, must be cognizant of the many pitfalls of violating the rules regulating patient confidentiality as established by federal and state privacy laws.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Latest:
Navigating work-life balance: VUMC’s Family Planning for Surgeons Series"I hope that [attendees] will be exposed to a community where they feel that they're able to freely ask questions, gain accurate information, and feel heard, validated, and connected," says Lauren E. Corona, MD.
Latest:
Jeffrey A. Albaugh, PhD, APRN, CUCNS, on editing the second edition of SUNA’s Core Curriculum"It was a daunting task, although I will say the original core was exceptional, so I had a wonderful framework from which to work," says Jeffrey A. Albaugh, PhD, APRN, CUCNS.
Latest:
Erosion of ring pessary with bladder rupture and complete eversion: A report of successful single-stage transvaginal repair"Major complications of ring pessaries are rare but present considerable challenges to surgeons and patients when they do occur," write E. Mackenzie Gibbs, MD, and Charles Lloyd Secrest, MD.
